KR102481242B1 - 암 진단에서 후생적 염색체 상호 작용의 적용 - Google Patents

암 진단에서 후생적 염색체 상호 작용의 적용 Download PDF

Info

Publication number
KR102481242B1
KR102481242B1 KR1020197019088A KR20197019088A KR102481242B1 KR 102481242 B1 KR102481242 B1 KR 102481242B1 KR 1020197019088 A KR1020197019088 A KR 1020197019088A KR 20197019088 A KR20197019088 A KR 20197019088A KR 102481242 B1 KR102481242 B1 KR 102481242B1
Authority
KR
South Korea
Prior art keywords
dna
chromosomal
sequence
probe
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197019088A
Other languages
English (en)
Korean (ko)
Other versions
KR20190086569A (ko
Inventor
프란시스 헥터 그랜드
어로울 셀밤 라마다스
알렉상드르 아쿨리츠체프
이완 헌터
Original Assignee
옥스포드 바이오다이나믹스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옥스포드 바이오다이나믹스 피엘씨 filed Critical 옥스포드 바이오다이나믹스 피엘씨
Publication of KR20190086569A publication Critical patent/KR20190086569A/ko
Application granted granted Critical
Publication of KR102481242B1 publication Critical patent/KR102481242B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2523/00—Reactions characterised by treatment of reaction samples
    • C12Q2523/10—Characterised by chemical treatment
    • C12Q2523/101—Crosslinking agents, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197019088A 2016-12-01 2017-11-30 암 진단에서 후생적 염색체 상호 작용의 적용 Active KR102481242B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428893P 2016-12-01 2016-12-01
US62/428,893 2016-12-01
PCT/GB2017/053615 WO2018100381A1 (en) 2016-12-01 2017-11-30 Application of epigenetic chromsomal interactions in cancer diagnostics

Publications (2)

Publication Number Publication Date
KR20190086569A KR20190086569A (ko) 2019-07-22
KR102481242B1 true KR102481242B1 (ko) 2022-12-23

Family

ID=60702831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019088A Active KR102481242B1 (ko) 2016-12-01 2017-11-30 암 진단에서 후생적 염색체 상호 작용의 적용

Country Status (12)

Country Link
US (2) US11560597B2 (enExample)
EP (2) EP4357463A3 (enExample)
JP (2) JP2019535295A (enExample)
KR (1) KR102481242B1 (enExample)
CN (1) CN110234769B (enExample)
AU (1) AU2017367245B2 (enExample)
CA (1) CA3045070A1 (enExample)
ES (1) ES2971286T3 (enExample)
MY (1) MY190153A (enExample)
PL (1) PL3548633T3 (enExample)
TW (1) TWI865427B (enExample)
WO (1) WO2018100381A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225551A1 (en) * 2019-05-08 2020-11-12 Oxford BioDynamics PLC Chromosome conformation markers of prostate cancer and lymphoma
CN118506860B (zh) * 2024-07-18 2024-10-08 广州女娲生命科技有限公司 药物表观遗传安全性评价的检测分析方法及系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036323A1 (en) 2008-09-25 2010-04-01 University Of Massachusetts Medical School Method of identifing interactions between genomic loci
JP2011521633A (ja) 2008-06-02 2011-07-28 オックスフォード バイオダイナミックス リミテッド 長距離染色体相互作用を検出する方法
WO2012159025A2 (en) * 2011-05-18 2012-11-22 Life Technologies Corporation Chromosome conformation analysis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564262A (en) * 2005-07-04 2010-02-26 Univ Erasmus Medical Ct Chromosome conformation capture-on-chip (4C) assay
GB0603251D0 (en) * 2006-02-17 2006-03-29 Isis Innovation DNA conformation
AU2008204338B2 (en) * 2007-01-11 2014-03-06 Erasmus University Medical Center Circular chromosome conformation capture (4C)
CA2609172A1 (en) * 2007-10-31 2009-04-30 University Of Utah Research Foundation Immunotherapy compositions for use with targeted therapy in the treatment of cancer
EP2366162A1 (en) * 2008-11-18 2011-09-21 Collabrx, Inc. Individualized cancer treatment
CA2804450C (en) * 2010-07-09 2022-10-11 Max Jan van Min 3-d genomic region of interest sequencing strategies
US20140056898A1 (en) * 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents
AU2013280644B2 (en) * 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN102827935B (zh) * 2012-08-29 2013-12-18 北京大学人民医院 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒
GB201320351D0 (en) * 2013-11-18 2014-01-01 Erasmus Universiteit Medisch Ct Method
JP2018518203A (ja) 2015-06-24 2018-07-12 オックスフォード バイオダイナミックス リミテッド エピジェネティックな染色体相互作用
EP3390656B1 (en) * 2015-12-14 2020-04-08 The General Hospital Corporation Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521633A (ja) 2008-06-02 2011-07-28 オックスフォード バイオダイナミックス リミテッド 長距離染色体相互作用を検出する方法
WO2010036323A1 (en) 2008-09-25 2010-04-01 University Of Massachusetts Medical School Method of identifing interactions between genomic loci
WO2012159025A2 (en) * 2011-05-18 2012-11-22 Life Technologies Corporation Chromosome conformation analysis

Also Published As

Publication number Publication date
WO2018100381A1 (en) 2018-06-07
CA3045070A1 (en) 2018-06-07
TW201842190A (zh) 2018-12-01
ES2971286T3 (es) 2024-06-04
TWI865427B (zh) 2024-12-11
NZ753716A (en) 2024-05-31
MY190153A (en) 2022-03-31
KR20190086569A (ko) 2019-07-22
CN110234769B (zh) 2024-06-07
US11560597B2 (en) 2023-01-24
AU2017367245B2 (en) 2020-09-24
EP3548633B1 (en) 2024-01-24
PL3548633T3 (pl) 2024-04-02
JP2023027076A (ja) 2023-03-01
US20230082230A1 (en) 2023-03-16
EP4357463A3 (en) 2024-07-17
EP3548633A1 (en) 2019-10-09
EP3548633C0 (en) 2024-01-24
JP7579003B2 (ja) 2024-11-07
AU2017367245A1 (en) 2019-06-06
CN110234769A (zh) 2019-09-13
EP4357463A2 (en) 2024-04-24
US20190338367A1 (en) 2019-11-07
JP2019535295A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
CN105102635B (zh) 肺癌的分类和可行性指数
Park et al. Molecular testing of brain tumor
KR102622309B1 (ko) 염색체 상호작용의 검출
CN111511930B (zh) 通过染色体相互作用遗传调节免疫响应
US11118232B2 (en) Methods of detecting DDR2 mutations
US20150080239A1 (en) Classification and Actionability Indices for Cancer
US20230082230A1 (en) Application of epigenetic chromosomal interactions in cancer diagnostics
AU2018344573A1 (en) Biomarker
HK40111334A (en) Application of epigenetic chromsomal interactions in cancer diagnostics
CN110225981A (zh) 分型方法
US10563267B2 (en) Polymorphism biomarkers predict clinical outcomes of cancer patients receiving regorafenib
HK40013967B (en) Application of epigenetic chromsomal interactions in cancer diagnostics
HK40013967A (en) Application of epigenetic chromsomal interactions in cancer diagnostics
US20240417801A1 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
KR20240006020A (ko) 염색체 상호작용 마커

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4